

Amendments to the Claims:

The following Listing of Claims replaces all prior versions and listings of the claims in the present application.

Listing of Claims:

Claims 1-10. (Cancelled)

Claim 11. (Currently Amended) A method for treating a patient having Metabolic Syndrome comprising Primary Insulin Resistance and exhibiting lipoprotein aberrations or hypertension, wherein said patient is not growth hormone deficient, wherein said method comprises administering to said patient human growth hormone or an analog thereof in an amount effective for decreasing lipoprotein aberrations or hypertension of said patient.

Claim 12. (Previously Presented) The method according to claim 11, wherein the human growth hormone comprises recombinant human growth hormone or an analog thereof.

Claim 13. (Previously Presented) The method according to claim 12, wherein said method comprises administering recombinant human growth hormone at about 9.5 µg/kg daily.

Claim 14. (Previously Presented) The method according to claim 11, wherein the treatment increases insulin sensitivity of the patient.

Claim 15. (Previously Presented) The method according to claim 11,
wherein the patient exhibits lipoprotein aberrations.

Claim 16. (Previously Presented) The method according to claim 16,
wherein the patient's serum concentration of triglyceride is decreased.

Claim 17. (Previously Presented) The method according to claim 11,
wherein the patient exhibits hypertension.

Claim 18. (Previously Presented) The method according to claim 17,
wherein the patient's diastolic blood pressure is reduced.

Claim 19. (Previously Presented) The method according to claim 12,
wherein said method comprises administering recombinant human growth hormone.